Additionally, the palmitate-dependent increased spare respiratory capacity (SRC) of endogenous CD37-negative (OciLy19, SUDHL6) lymphoma cell lines was lost when treated with the CPT1a inhibitor (Fig. S6K–N), whereas no effect of palmitate supplementation in combination with CPT1a inhibition was observed in endogenous CD37-positive (OciLy8, WSU-NHL) lymphoma cells (Fig. S6G–J). Here, CPT1A is linked to non-Hodgkin lymphoma.